This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

Mode of action

Cibinqo (abrocitinib) is a small molecule that works inside the cell to inhibit JAK11 ​​​​​​​

Cibinqo is a Janus kinase (JAK)1 inhibitor.1

JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cell surface to influence haematopoiesis and immune cell function.1

JAKs phosphorylate and activate STATs, which in turn modulate activity in the cell. Inhibition of JAK1 interrupts signalling pathways by preventing the phosphorylation and activation of STATs.1

Key cytokines signal through JAK11-10

By inhibiting JAK1, production of key signalling cytokines that drive AD inflammation, itch and skin barrier disruption are decreased.1–5

INFLAMMATION2,7

IL-4 and IL-13 are important mediators of type 2 inflammation and are major drivers of atopic inflammation.

ITCH2,4,6

IL-31 is a type 2 inflammatory cytokine that plays a role in mediating itch and atopic inflammation.

TSLP has been shown to promote atopic inflammation and is believed to play a role in itch.

BARRIER DISRUPTION2,4

IL-22 helps induce epidermal hyperplasia and skin barrier disruption in AD.

In addition to the roles of the cytokines described here, these, and other cytokines are believed to play multiple roles in AD pathophysiology.8,9

The role of the JAK/STAT pathway

The JAK/STAT pathway is believed to be an important mediator of the pathophysiology of atopic dermatitis.11 JAKs are a family of intracellular cytoplasmic protein tyrosine kinases that are associated with cytokine and growth factor receptor subunits.2,3,10–12

Upon binding of proinflammatory cytokines, cytokine receptors dimerise, bringing JAK pairs into close proximity​​​​​​​.2,3,10–12

The paired JAKs then phosphorylate and activate each other​​​​​​​.2,3,10–12

JAK-mediated phosphorylation of the cytokine receptor creates a binding site for STATs.2,3,10–12

STATs are recruited and phosphorylated by activated JAKs.2,3,10–12

Activated STAT dimers move into the nucleus resulting in increased transcription of proinflammatory cytokine genes.2,3,10–12

Explore more

Efficacy

Cibinqo has been studied across six Phase III trials as monotherapy or in combination with medicated topical therapies.1–7

Explore the JADE clinical trials

References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics. 2. Bieber T, et al. N Eng J Med 2021;384:1101–1112. 3. Simpson E, et al. Lancet 2020;395:P255–266. 4. Silverberg J, et al. JAMA Dermatol 2021;156(8):863–873. 5. Blauvelt A, et al. JAAD 2021;doi.org/10/1016/j.jaad.2021.05.075. 6. Eichenfield L, et al. JAMA Dermatol 2021;doi: 10.1001/jamadermatol.2021.2830. 7. ClinicalTrials.gov. NCT03422822. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03422822.

Safety

3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

View safety guidance

References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.

AD=atopic dermatitis; IL=interleukin; JAK=Janus kinase; STAT=signal transducer and activator of transcription; TSLP=thymic stromal lymphopoietin.

Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics. 2. Hammarén HM, et al. Cytokine 2019;118:48–63. 3. Paller AS, et al. J Allergy Clin Immunol. 2017;140(3):633–643. 4. Guttman-Yassky E, et al. Expert Opin Biol Ther 2013;13(4):549–561. 5. Mollanazar NK, et al. Clin Rev Allergy Immunol 2016;51(3):263–292. 6. Čepelak I, et al. Biochem Med (Zagreb) 2019;29(2):020501. 7. Weidinger S, Novak N. Lancet 2016;387(10023):1109–1122. 8. Howell MD, et al. Front Immunol 2019;10:2342. 9. Langan SM, et al. Lancet 2020;396(10247):345–360. 10. Morris R, et al. Protein Sci 2018;27(12):1984–2009. 11. Clark JD, et al. J Med Chem 2014; 57(12):5023–5038. 12. Damsky W, King BA. J Am Acad Dermatol 2017;76(4):736–744.
PP-CIB-GBR-0054. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Alert Card and Prescriber Checklists, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Alert Card.

Mode of action

  • Key cytokines signal through JAK1
  • The role of the JAK/STAT pathway

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No